{
    "nct_id": "NCT05178043",
    "official_title": "A Phase II Study to Evaluate the Efficacy and Safety of GT90001 in Combination With Nivolumab as a Second-line Treatment in Subjects With Advanced Hepatocellular Carcinoma",
    "inclusion_criteria": "* Subjects must have confirmed diagnosis of aHCC (locally advanced or metastatic hepatocellular carcinoma) by radiography, histology and/or cytology, not eligible for surgical and/or locoregional therapies; or progressive disease after surgical and/or locoregional therapies (fibrolamellar, sarcomatoid HCC and mixed hepatocellular / cholangiocarcinoma subtypes are not eligible);\n* Have Barcelona Clinic Liver Cancer (BCLC) Stage C disease or BCLC Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy;\n* Have documented disease progression after or intolerance to first line treatment of immune checkpoint inhibitors(ICI)\n* Child-Pugh score â‰¤ 6 (Child-Pugh A) score within 7 days of first dose of study drug;\n* ECOG performance status: 0-1 within 7 days of first dose of study drug;\n* Have a predicted life expectancy of greater than 3 months;\n* Adequate hematologic and end-organ function functions of the important organs are confirmed.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Presence of tumor thrombus involving main trunk of portal vein (Vp4), inferior vena cava, cardiac involvement of HCC;\n* Subjects with untreated or incompletely treated varices with bleeding or high-risk for bleeding. Has had esophageal or gastric variceal bleeding within the last 6 months;\n* History of encephalopathy;\n* Has a known history of, or any evidence of central nervous system (CNS) metastases and/or carcinomatous meningitis;\n* Had history of a solid organ or hematologic transplant;\n* Has received locoregional therapy to liver (TACE, TAE, hepatic arterial infusion [HAI], radiation, radioembolization or ablation) within 4 weeks of start of study treatment.\n* Had prior systemic TKI treatment prior to start of study treatment;\n* Has received prior immune checkpoint inhibitors within 4 weeks of start of study treatment;\n* Has received Nivolumab in the first-line systemic therapy:\n* Active co-infection with:\n\n  1. Both hepatitis B and C as evidenced by positive HBV surface antigen or detectable HBV DNA and HCV RNA, OR\n  2. Hepatitis D infection in subjects with hepatitis B\n* Has an active bacterial or fungal infection requiring systemic therapy within 7 days prior to study drug dosing;\n* Has a known history of active tuberculosis (Bacillus Tuberculosis);\n* Serious, non-healing or dehiscing wound, active ulcer, or untreated bone fracture;\n* Thrombotic or embolic events (except HCC tumor thrombus) within the past 6 months, such as cerebrovascular accident (including transient ischemic attacks), pulmonary embolism; If prior history of deep vein thrombosis (DVT) / (pulmonary embolism (PE), the subject needs to be on stable doses of anticoagulation with low molecular weight heparin or oral anticoagulant for at least two weeks;\n* Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.\n* Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis;\n* Subjects with any other serious disease considered by the investigator not in the condition to enter into the trial;",
    "miscellaneous_criteria": ""
}